NuVasive Executive Compensation (FY22)
NUVA · Executive and director compensation, fiscal 2022 only
The NuVasive brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 12, 2026Latest filing (8-K): June 9, 2023
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
163 figures on this page: 156 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is NuVasive's chief executive and what were they paid?
J. Christopher Barry was paid $8,077,095 in total compensation as Chief Executive Officer for fiscal 2022.
What was NuVasive's say-on-pay result?
The say-on-pay proposal drew 52.2% support at the meeting held June 9, 2023 for fiscal 2022.
Which companies are in NuVasive's peer group?
The disclosed peer group names Avanos Medical, Inc., CONMED Corporation, Dexcom, Inc., Globus Medical, Inc. and Haemonetics Corporation, among others.
What is NuVasive's chief executive pay ratio?
The company reported a chief executive pay ratio of 118:1 for fiscal 2022, against median employee compensation of $68,396.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
J. Christopher Barry Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Matthew Harbaugh Executive Vice President, Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Massimo Calafiore Former Executive Vice President, Chief Commercial Officer Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Nathaniel Sisitsky Senior Vice President, General Counsel and Corporate Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Dale Wolf Senior Vice President, Global Operations | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Farrington Senior Vice President, People and Culture | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Dale Wolf | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Dale Wolf | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| J. Christopher Barry | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| J. Christopher Barry | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Massimo Calafiore | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Massimo Calafiore | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Matthew K. Harbaugh | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Matthew K. Harbaugh | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael Farrington | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael Farrington | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Nathaniel B. Sisitsky | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Nathaniel B. Sisitsky | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Matthew Harbaugh | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| J. Christopher Barry | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Dale Wolf | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Nathaniel Sisitsky | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Michael Farrington | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2022
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Daniel J. Wolterman Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Vickie L. Capps | ◇ | ◇ | — | — | — | — | ◇ |
Leslie V. Norwalk | ◇ | ◇ | — | — | — | — | ◇ |
Robert F. Friel | ◇ | ◇ | — | — | — | — | ◇ |
Amy Belt Raimundo | ◇ | ◇ | — | — | — | — | ◇ |
John A. DeFord | ◇ | ◇ | — | — | — | — | ◇ |
Siddhartha C. Kadia | ◇ | ◇ | — | — | — | — | ◇ |
R. Scott Huennekens | ◇ | ◇ | — | — | — | — | ◇ |
Donald J. Rosenberg | ◇ | — | — | — | — | — | ◇ |
J. Christopher Barry served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
- Avanos Medical, Inc. AVNS
- CONMED Corporation CNMD
- Dexcom, Inc. DXCM
- Globus Medical, Inc. GMED
- Haemonetics Corporation HAE
- ICU Medical, Inc. ICUI
- Integer Holdings Corp ITGR
- Integra LifeSciences Holdings Corp IART
- LivaNova PLC LIVN
- Masimo Corporation MASI
- Merit Medical Systems Inc. MMSI
- Nevro Corp. NVRO
- Orthofix Medical, Inc. OFIX
- QuidelOrtho Corporation QDEL
- ResMed, Inc. RMD
- STERIS Plc STE
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2022 | June 9, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 11, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 18, 2021 | = | ◇ | ◇ | ◇ |
| 2018 | May 9, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 3, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | May 18, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | May 19, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact NuVasive disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where NuVasive sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
NuVasive recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
163 figures on this page: 156 cited to the filing that reported them, 7 calculated from figures it prints.
156 cited to the filing
7 calculated from the filing
Documents cited
- 0001142596-23-000030Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-23-1382792022 Summary Compensation Table · CEO Pay Ratio · Director Compensation · Grants of Plan-Based Awards for 2022 · and 1 more section
- 0001142596-22-000017Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-028869Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-19-018561Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-18-010750Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-17-011283Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-16-597735Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “NuVasive executive compensation, FY2022.” https://intel.velarion.ai/comp/NUVA (accessed 2026).
Short form: data: Velarion
The NuVasive brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about NuVasive and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers NuVasive discloses
The companies named in NUVA's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}